Our first pipeline Neu-001,Neu-001, an innovative first-in-class small-molecule drug for treating amblyopia (commonly known as lazy eye), has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA). This milestone achievement was unveiled at a press conference held on December 17 at the Hong Kong Science Park, marking the first FDA approval for a novel chemical drug developed under Hong Kong’s prestigious InnoHK research platform. The press conference was hosted by Professor Guangjin Pan, Director of the Centre for Regenerative Medicine and  Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences. Key attendees…